Organon & Co. is currently covered by seven research firms that collectively assign a consensus recommendation of “Reduce.” Four analysts carry sell ratings, two recommend holding the shares, and one maintains a strong buy rating. Over the past six months, JPMorgan Chase & Co. shifted its stance to underweight while lowering its target, Piper Sandler moved from overweight to underweight, and Barclays initiated coverage with an underweight view. Wall Street Zen stands out as the sole upgrade in the period, moving Organon from hold to buy, indicating a lack of conviction among the analyst community despite one bullish outlier.

In its latest quarterly report, Organon delivered adjusted earnings per share of $1.01, surpassing the consensus estimate of $0.93 by approximately 8.6%. Revenue reached $1.60 billion, topping forecasts by around 1.9%. The company achieved a net margin of 7.95% and an exceptional return on equity of 143.47%, though EPS was down from $1.38 in the prior-year period. Analysts now forecast full-year EPS of 3.68, implying moderate growth expectations despite year-over-year headwinds in profitability.

Institutional ownership remains high at 77.43%, reflecting strong interest from major asset managers. During the third quarter, Vanguard Group increased its stake by 11.3%, adding 3.65 million shares to reach a total holding valued at approximately $384 million. AQR Capital Management also boosted its position by 28.3%, while Gotham Asset Management grew by 37.2%. State Street and Nordea Investment Management respectively raised their stakes by 6.0% and 1.1%, underscoring continued confidence among large fiduciaries despite mixed analyst sentiment.

Organon maintains a solid liquidity profile with a current ratio of 1.75 and a quick ratio of 1.20, while its debt-to-equity ratio stands at 9.69, reflecting a leveraged balance sheet typical of a spin-out entity. The company’s market capitalization is approximately $2.19 billion, with a price-to-earnings ratio of 4.39 and a PEG ratio of 1.68, indicating that earnings growth expectations are modest relative to valuation. Organon pays a quarterly dividend of $0.02 per share, translating to an annualized yield of 0.9% and a payout ratio of 4.17%, suggesting conservative cash distribution policies amid reinvestment priorities.